27975209|t|Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia
27975209|a|Post-bariatric hypoglycaemia (PBH) is a rare, but severe, metabolic disorder arising months to years after bariatric surgery. It is characterised by symptomatic postprandial hypoglycaemia, with inappropriately elevated insulin concentrations. The relative contribution of exaggerated incretin hormone signalling to dysregulated insulin secretion and symptomatic hypoglycaemia is a subject of ongoing inquiry. This study was designed to test the hypothesis that PBH and associated symptoms are primarily mediated by glucagon-like peptide-1 (GLP-1). We conducted a double-blinded crossover study wherein eight participants with confirmed PBH were assigned in random order to intravenous infusion of the GLP-1 receptor (GLP-1r) antagonist. Exendin (9-39) (Ex-9), or placebo during an OGTT on two separate days at the Stanford University Clinical and Translational Research Unit. Metabolic, symptomatic and pharmacokinetic variables were evaluated. Results were compared with a cohort of BMI - and glucose -matched non-surgical controls (NSCs). Infusion of Ex-9 decreased the time to peak glucose and rate of glucose decline during OGTT, and raised the postprandial nadir by over 70%, normalising it relative to NSCs and preventing hypoglycaemia in all PBH participants. Insulin AUC and secretion rate decreased by 57% and 71% respectively, and peak postprandial insulin was normalised relative to NSCs. Autonomic and neuroglycopenic symptoms were significantly reduced during Ex-9 infusion. GLP-1r blockade prevented hypoglycaemia in 100% of individuals, normalised beta cell function and reversed neuroglycopenic symptoms, supporting the conclusion that GLP-1 plays a primary role in mediating hyperinsulinaemic hypoglycaemia in PBH. Competitive antagonism at the GLP-1r merits consideration as a therapeutic strategy. ClinicalTrials.gov NCT02550145.
27975209	18	23	GLP-1	T116	C0061355
27975209	27	38	symptomatic	T169	C0231220
27975209	39	67	post-bariatric hypoglycaemia	T047	C0020615
27975209	68	96	Post-bariatric hypoglycaemia	T047	C0020615
27975209	98	101	PBH	T047	C0020615
27975209	108	112	rare	T080	C0522498
27975209	118	124	severe	T080	C0205082
27975209	126	144	metabolic disorder	T047	C0025517
27975209	153	159	months	T079	C0439231
27975209	163	168	years	T079	C0439234
27975209	175	192	bariatric surgery	T061	C1456587
27975209	217	228	symptomatic	T169	C0231220
27975209	229	241	postprandial	T079	C0376674
27975209	242	255	hypoglycaemia	T047	C0020615
27975209	287	294	insulin	T116,T121,T125	C0021641
27975209	295	309	concentrations	T081	C1264643
27975209	340	351	exaggerated	T080	C0442801
27975209	352	368	incretin hormone	T116,T121,T125	C1562292
27975209	369	379	signalling	T038	C3537152
27975209	383	395	dysregulated	T077	C3887504
27975209	396	413	insulin secretion	T043	C1256369
27975209	418	429	symptomatic	T169	C0231220
27975209	430	443	hypoglycaemia	T047	C0020615
27975209	468	475	inquiry	T052	C2987583
27975209	482	487	study	T062	C2603343
27975209	513	523	hypothesis	T078	C1512571
27975209	529	532	PBH	T047	C0020615
27975209	548	556	symptoms	T184	C1457887
27975209	583	606	glucagon-like peptide-1	T116	C0061355
27975209	608	613	GLP-1	T116	C0061355
27975209	631	645	double-blinded	T062	C0013072
27975209	646	661	crossover study	T062	C0150097
27975209	676	688	participants	T098	C0679646
27975209	704	707	PBH	T047	C0020615
27975209	741	761	intravenous infusion	T061	C0021440
27975209	769	783	GLP-1 receptor	T192	C0378073
27975209	785	791	GLP-1r	T192	C0378073
27975209	793	803	antagonist	T120	C0003139
27975209	805	819	Exendin (9-39)	T116	C0247947
27975209	821	825	Ex-9	T116	C0247947
27975209	831	838	placebo	T061	C0032042
27975209	849	853	OGTT	T060	C0029161
27975209	882	901	Stanford University	T073,T092	C0041740
27975209	902	942	Clinical and Translational Research Unit	T093	C1274109
27975209	944	953	Metabolic	T169	C0311400
27975209	955	966	symptomatic	T169	C0231220
27975209	971	996	pharmacokinetic variables	T169	C0031328
27975209	1042	1048	cohort	T098	C0599755
27975209	1052	1055	BMI	T201	C1305855
27975209	1062	1069	glucose	T109,T121,T123	C0017725
27975209	1079	1100	non-surgical controls	T096	C0009932
27975209	1102	1106	NSCs	T096	C0009932
27975209	1109	1117	Infusion	T061	C0574032
27975209	1121	1125	Ex-9	T116	C0247947
27975209	1153	1160	glucose	T109,T121,T123	C0017725
27975209	1165	1169	rate	T081	C1521828
27975209	1173	1180	glucose	T109,T121,T123	C0017725
27975209	1196	1200	OGTT	T060	C0029161
27975209	1217	1229	postprandial	T079	C0376674
27975209	1230	1235	nadir	T080	C1708760
27975209	1276	1280	NSCs	T096	C0009932
27975209	1296	1309	hypoglycaemia	T047	C0020615
27975209	1317	1320	PBH	T047	C0020615
27975209	1321	1333	participants	T098	C0679646
27975209	1335	1342	Insulin	T116,T121,T125	C0021641
27975209	1343	1346	AUC	T081	C0376690
27975209	1351	1360	secretion	T042	C0312431
27975209	1361	1365	rate	T081	C1521828
27975209	1414	1426	postprandial	T079	C0376674
27975209	1427	1434	insulin	T116,T121,T125	C0021641
27975209	1462	1466	NSCs	T096	C0009932
27975209	1468	1477	Autonomic	T033	C2674101
27975209	1482	1506	neuroglycopenic symptoms	T184	C1457887
27975209	1541	1545	Ex-9	T116	C0247947
27975209	1546	1554	infusion	T061	C0574032
27975209	1556	1562	GLP-1r	T192	C0378073
27975209	1582	1595	hypoglycaemia	T047	C0020615
27975209	1607	1618	individuals	T098	C0237401
27975209	1631	1649	beta cell function	T043	C0007613
27975209	1654	1687	reversed neuroglycopenic symptoms	T184	C1457887
27975209	1720	1725	GLP-1	T116	C0061355
27975209	1760	1791	hyperinsulinaemic hypoglycaemia	T047	C1864903
27975209	1795	1798	PBH	T047	C0020615
27975209	1812	1822	antagonism	T044	C0013159
27975209	1830	1836	GLP-1r	T192	C0378073
27975209	1863	1883	therapeutic strategy	T169	C0039798